J&J misses revenue estimates as blockbuster drugs disappoint
- Johnson & Johnson on Wednesday forecast full-year profit largely below expectations, after posting a rare miss on quarterly revenue as sales of some of its major drugs fell short of Wall Street expectations.
J&J’s pharmaceuticals unit, which makes up half of the overall sales and produces blockbuster drugs such as Imbruvica and Stelara, has powered much of the company’s recent growth even as it works to improve the performance of its medical device and consumer health units. Sales of psoriasis drug Stelara rose 17.7% to $1.70 billion, missing Credit Suisse’s estimate of $1.79 billion. Cancer drug Imbruvica’s sales rose 24.5% to $875 million, although they missed the brokerage’s estimate of $907 million.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
IBM forecasts full-year profit above estimates on cloud growthInternational Business Machines Corp forecast full-year profit above market expe...
Read more »
Netflix subscriber forecast misses Wall Street estimate as market leader faces DisneyNetflix missed Wall Street subscriber forecasts for the first quarter, amid pressure from lower-cost services from Disney and Apple in the streaming video wars. More here:
Read more »
UBS misses targets, dials back ambitionsUBS missed its targets in the fourth quarter as wealthy clients took $4.7 billion of their money elsewhere
Read more »
United Airlines profits surge nearly 40% on cheaper fuel and strong demandThe Chicago-based carrier reported earnings and revenue on Tuesday that narrowly beat analysts' estimates, sending shares up slightly in postmarket trading.
Read more »
United Airlines Reports Stronger Profit, RevenueUnited Airlines reported higher profit in the latest quarter on stronger revenue and lower fuel costs, despite challenges from the grounding of Boeing’s 737 MAX.
Read more »
Netflix Falls Short of Its Domestic Subscriber ForecastThe streaming giant missed its forecast for subscriber growth in the U.S., a performance that comes as the company faces heightened competition from a gaggle of rivals.
Read more »